Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

NCT03798639 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Merkel Cell Carcinoma
Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8
Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
RADIATION: Radiation Therapy

Sponsor

Claire Verschraegen